Literature DB >> 18588301

Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations.

Jacob G Zeevaart1, Ligong Wang, Vinay V Thakur, Cheryl S Leung, Julian Tirado-Rives, Christopher M Bailey, Robert A Domaoal, Karen S Anderson, William L Jorgensen.   

Abstract

Efficient optimization of an inactive 2-anilinyl-5-benzyloxadiazole core has been guided by free energy perturbation (FEP) calculations to provide potent non-nucleoside inhibitors of human immunodeficiency virus (HIV) reverse transcriptase (NNRTIs). An FEP "chlorine scan" was performed to identify the most promising sites for substitution of aryl hydrogens. This yielded NNRTIs 8 and 10 with activities (EC50) of 820 and 310 nM for protection of human T-cells from infection by wild-type HIV-1. FEP calculations for additional substituent modifications and change of the core heterocycle readily led to oxazoles 28 and 29, which were confirmed as highly potent anti-HIV agents with activities in the 10-20 nM range. The designed compounds were also monitored for possession of desirable pharmacological properties by use of additional computational tools. Overall, the trends predicted by the FEP calculations were well borne out by the assay results. FEP-guided lead optimization is confirmed as a valuable tool for molecular design including drug discovery; chlorine scans are particularly attractive since they are both straightforward to perform and highly informative.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18588301      PMCID: PMC2677907          DOI: 10.1021/ja8019214

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  29 in total

1.  Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.

Authors:  Robert C Rizzo; Marina Udier-Blagović; De-Ping Wang; Edward K Watkins; Marilyn B Kroeger Smith; Richard H Smith; Julian Tirado-Rives; William L Jorgensen
Journal:  J Med Chem       Date:  2002-07-04       Impact factor: 7.446

Review 2.  Molecular modeling of organic and biomolecular systems using BOSS and MCPRO.

Authors:  William L Jorgensen; Julian Tirado-Rives
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

3.  FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase.

Authors:  Joseph T Kim; Andrew D Hamilton; Christopher M Bailey; Robert A Domaoal; Robert A Domoal; Ligong Wang; Karen S Anderson; William L Jorgensen
Journal:  J Am Chem Soc       Date:  2006-12-06       Impact factor: 15.419

4.  Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains.

Authors:  Daniel M Himmel; Kalyan Das; Arthur D Clark; Stephen H Hughes; Abdellah Benjahad; Said Oumouch; Jérôme Guillemont; Sophie Coupa; Alain Poncelet; Imre Csoka; Christophe Meyer; Koen Andries; Chi Hung Nguyen; David S Grierson; Eddy Arnold
Journal:  J Med Chem       Date:  2005-12-01       Impact factor: 7.446

5.  Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture.

Authors:  D Richman; C K Shih; I Lowy; J Rose; P Prodanovich; S Goff; J Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

6.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

7.  Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro.

Authors:  T S Lin; M Z Luo; M C Liu; S B Pai; G E Dutschman; Y C Cheng
Journal:  Biochem Pharmacol       Date:  1994-01-20       Impact factor: 5.858

8.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.

Authors:  Kalyan Das; Arthur D Clark; Paul J Lewi; Jan Heeres; Marc R De Jonge; Lucien M H Koymans; H Maarten Vinkers; Frederik Daeyaert; Donald W Ludovici; Michael J Kukla; Bart De Corte; Robert W Kavash; Chih Y Ho; Hong Ye; Mark A Lichtenstein; Koen Andries; Rudi Pauwels; Marie-Pierre De Béthune; Paul L Boyer; Patrick Clark; Stephen H Hughes; Paul A J Janssen; Eddy Arnold
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

9.  Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives.

Authors:  T Haertle; C J Carrera; D B Wasson; L C Sowers; D D Richman; D A Carson
Journal:  J Biol Chem       Date:  1988-04-25       Impact factor: 5.157

Review 10.  The design of drugs for HIV and HCV.

Authors:  Erik De Clercq
Journal:  Nat Rev Drug Discov       Date:  2007-12       Impact factor: 84.694

View more
  29 in total

Review 1.  Prediction of protein-ligand binding affinity by free energy simulations: assumptions, pitfalls and expectations.

Authors:  Julien Michel; Jonathan W Essex
Journal:  J Comput Aided Mol Des       Date:  2010-05-28       Impact factor: 3.686

2.  Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.

Authors:  Bingjie Qin; Xingkai Jiang; Hong Lu; Xingtao Tian; Florent Barbault; Li Huang; Keduo Qian; Chin-Ho Chen; Rong Huang; Shibo Jiang; Kuo-Hsiung Lee; Lan Xie
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

Review 3.  Identification of HIV inhibitors guided by free energy perturbation calculations.

Authors:  Orlando Acevedo; Zandrea Ambrose; Patrick T Flaherty; Hadega Aamer; Prashi Jain; Somisetti V Sambasivarao
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 4.  Entropy-enthalpy compensation: role and ramifications in biomolecular ligand recognition and design.

Authors:  John D Chodera; David L Mobley
Journal:  Annu Rev Biophys       Date:  2013       Impact factor: 12.981

5.  Enhancing Side Chain Rotamer Sampling Using Nonequilibrium Candidate Monte Carlo.

Authors:  Kalistyn H Burley; Samuel C Gill; Nathan M Lim; David L Mobley
Journal:  J Chem Theory Comput       Date:  2019-02-11       Impact factor: 6.006

6.  Structural characterization and computer-aided optimization of a small-molecule inhibitor of the Arp2/3 complex, a key regulator of the actin cytoskeleton.

Authors:  Andrew W Baggett; Zoe Cournia; Min Suk Han; George Patargias; Adam C Glass; Shih-Yuan Liu; Brad J Nolen
Journal:  ChemMedChem       Date:  2012-05-23       Impact factor: 3.466

7.  Computer-aided discovery of anti-HIV agents.

Authors:  William L Jorgensen
Journal:  Bioorg Med Chem       Date:  2016-07-21       Impact factor: 3.641

8.  Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.

Authors:  Maria Nicoline Baandrup Kristiansen; Sanne Skovgård Veidal; Kristoffer Tobias Gustav Rigbolt; Kirstine Sloth Tølbøl; Jonathan David Roth; Jacob Jelsing; Niels Vrang; Michael Feigh
Journal:  World J Hepatol       Date:  2016-06-08

9.  Energetics of displacing water molecules from protein binding sites: consequences for ligand optimization.

Authors:  Julien Michel; Julian Tirado-Rives; William L Jorgensen
Journal:  J Am Chem Soc       Date:  2009-10-28       Impact factor: 15.419

10.  Path-integral method for predicting relative binding affinities of protein-ligand complexes.

Authors:  Chandrika Mulakala; Yiannis N Kaznessis
Journal:  J Am Chem Soc       Date:  2009-04-01       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.